Released on = November 30, 2006, 10:37 am

Press Release Author = Dr. Mark Pearson

Industry = Pharmaceuticals

Press Release Summary = After positive clinical trials for a leading alzheimer\'s
drug candidate, Neuromedix is plannig to move on throught the next phase of
development for this new drug.

Press Release Body = TORONTO, Ontario - November 16, 2006: NeuroMedix Inc.
("NeuroMedix" or the "Company") (TSXV: NMX) today announced that based on the
positive pre-clinical development data received to date for its lead product,
Minozac, it will now explore licensing or acquisition transactions with a view to
maximizing shareholder value.

"As we complete the final stages of our pre-clinical development program and prepare
towards the submission of our Phase I safety application to the regulatory
authorities, our Board of Directors has directed management to seek strategic
alliances with pharmaceutical and biotechnology partners and to explore merger and
acquisition transactions", said Dr. Mark L. Pearson, Chief Executive Officer,
"Consistent with our business strategy, we plan to seek partners or acquirers with
the financial resources to further advance the clinical development of Minozac in a
bid to ensure Minozac's rapid development to benefit patients with Alzheimer's and
other neuroinflammatory brain indications. Our Board has assessed Minozac's
commercial potential in several large markets, including the treatment of
Alzheimer's disease, and believes this path will maximize value to NeuroMedix
shareholders."

As a first step in this business strategy, NeuroMedix plans to complete an interim
financing before the end of the year.

NeuroMedix provides no assurance that the implementation of a process to explore
licensing or acquisition transactions with a view to maximizing shareholder value
will result in a transaction. No decision has been made to enter into any
transaction at this time. The Company will retain investment bankers to provide
financial advice to NeuroMedix in this process.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic
agents for the treatment of degenerative and inflammatory diseases of the central
nervous system, such as Alzheimer's disease, traumatic brain injury, neuropathic
pain, age-related macular degeneration and multiple sclerosis. Our therapeutic drug
candidates are based on research from a team of leading experts in the field of
neuroinflammation at Northwestern University and have been demonstrated to reduce
brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive
function in an Alzheimer's disease animal model in mice. Our lead candidate, Minozac
has also been shown to reduce inflammation and prevent loss of cognitive function in
mice suffering traumatic brain injury. Based on these findings, NeuroMedix is
pursuing the development of its lead compound for Alzheimer's disease and traumatic
brain injury in humans. NeuroMedix's shares are listed on the TSX Venture Exchange
under the symbol "NMX".



Web Site = http://www.neuromedixinc.com

Contact Details = Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
425-503-5156
mark@neuromedixinc.com